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Abstract
Background: Pneumocystis jirovecii remains an important cause of fatal pneumonia (Pneumocystis pneumonia or PcP) in
HIV+ patients and other immunocompromised hosts. Despite many previous attempts, a clinically useful serologic test for P.
jirovecii infection has never been developed.
Methods/Principal Findings: We analyzed serum antibody responses to the P. jirovecii major surface glycoprotein
recombinant fragment C1 (MsgC1) in 110 HIV+ patients with active PcP (cases) and 63 HIV+ patients with pneumonia due to
other causes (controls) by an enzyme-linked immunosorbent assay (ELISA). The cases had significantly higher IgG and IgM
antibody levels to MsgC1 than the controls at hospital admission (week 0) and intervals up to at least 1 month thereafter.
The sensitivity, specificity and positive predictive value (PPV) of IgG antibody levels increased from 57.2%, 61.7% and 71.5%
at week 0 to 63.4%, 100%, and 100%, respectively, at weeks 3–4. The sensitivity, specificity and PPV of IgM antibody levels
rose from 59.7%, 61.3%, and 79.3% at week 0 to 74.6%, 73.7%, and 89.8%, respectively, at weeks 3–4. Multivariate analysis
revealed that a diagnosis of PcP was the only independent predictor of high IgG and IgM antibody levels to MsgC1. A high
LDH level, a nonspecific marker of lung damage, was an independent predictor of low IgG antibody levels to MsgC1.
Conclusions/Significance: The results suggest that the ELISA shows promise as an aid to the diagnosis of PCP in situations
where diagnostic procedures cannot be performed. Further studies in other patient populations are needed to better define
the usefulness of this serologic test.
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Introduction
Pneumocystis jirovecii pneumonia (PcP) was the leading cause of
morbidity and mortality in HIV+ patients early in the HIV/AIDS
epidemic [1–3]. With the introduction and wide use of highly
active antiretroviral therapy (ART) and PcP chemoprophylaxis,
the incidence of PcP in this patient population has declined.
However, PcP remains an important clinical problem in HIV+
and other immunocompromised patients with mortality rates
ranging from 10–60% depending on the underlying disease [2–3].
Definitive diagnosis of PcP is usually made by the microscopic
demonstration of the organism in specimens obtained by induced
sputum or bronchoalveolar lavage fluid (BALF) with histological or
immunofluorescent reagents [4]. Often, HIV+ patients with a
suggestive clinical picture of PcP are treated empirically for PcP
[5]. In such cases, non-invasive and non-specific methods such as
chest radiographs, serum lactic dehydrogenase (LDH), or serum b-
glucan levels may be used to help support the diagnosis [6–9].
Detection of P. jirovecii DNA by polymerase chain reaction (PCR) is
highly sensitive; however, this test is not commercially available,
and the high rate of P. jirovecii colonization in HIV+ patients can
make PCR results difficult to interpret [10].
The availability of a reliable and sensitive serological test for P.
jirovecii infection, particularly if it involved only a single specimen,
is attractive because it would provide a degree of specificity to
currently available non-invasive tests described above. Serologic
studies have been investigated for many years, but the reagents
used could not reliably distinguish present from past P. jirovecii
infection or colonization from active disease [11–19]. Since
Pneumocystis cannot be reliably grown in vitro, it has been difficult
to obtain large quantities of purified proteins for use as antigens for
assay development.
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developed that show promise as reagents for serologic studies:
Kexin 1, which is encoded by a single gene; the major surface
glycoprotein (Msg), which is encoded by multiple genes and is
capable of antigenic variation [20–21]. Both antigens are highly
immunogenic and contain protective epitopes [19–23]. We have
focused our attention on Msg. First we developed 3 overlapping
recombinant fragments (MsgA, MsgB, MsgC1) that span the entire
length of a single Msg isoform for our studies [24–25]. Then we
developed variants (MsgC 3, 8, and 9) of Msg C1 in order to better
define the reactivity of serum antibodies [26].
We have shown that MsgC1 is helpful in distinguishing HIV+
patients who have had previous PcP from those who did not and in
differentiating healthcare workers who had contact with patients
from those who did not [24–25,27]. We also examined the serologic
responses to P. jirovecii infection in early childhood; geographic
differences in seroreactivity to MsgC1; and the specific factors
independently related to high antibody levels to MsgC1 in long-
term cohort study [28–31]. In addition, we conducted a pilot study
to examine the serologic responses in HIV+ patients admitted to the
San Francisco General Hospital (SFGH) with PcP (cases) and
pneumonia due other causes (controls) [32]. The data showed that
first episode of PcP and CD4+ counts $50 cells/mL were the
principal host factors associated with a rise in antibody response to
MsgC1. While this report was of interest, it was limited by the
relatively small number of cases and lack of convalescent serum
specimens in the controls. In addition, the study only examined IgG
antibodies and provided only modest information about the
influence host factors had on these antibodies.
Since the pilot study, we have increased the number of SFGH
HIV+ cases and controls with acute and convalescent serum
specimens. We have also improved the IgG assay and developed an
assay to measure IgM antibody responses to MsgC1. We undertook
the present study to: 1) characterize the IgG and IgM antibody
responses to MsgC1 in the cases and the controls; 2) evaluate these
antibody responses in the diagnosis of PcP; and 3) identify specific
host or environmental factors associated with these antibodies. The
data show that there are significant differences in IgG and IgM
levels between cases and controls at multiple time points, which
suggest that this serologictest maybe helpful inthediagnosis ofPcP.
Materials and Methods
Patient population
The study was approved by the University of California San
Francisco and the University of Cincinnati Institutional Review
Boards, and all patients provided written, informed consent for
participation in the study. As standard clinical practice, all HIV+
patients admitted to SFGH with respiratory symptoms were
evaluated by a uniform diagnostic protocol previously described
[33]. The diagnosis of PcP was confirmed by visualization of the
organism in induced sputum or bronchoalveolar lavage fluid (BALF)
specimen (cases) using Diff-Quik stain, which is a modified Giemsa
stain, which identifies all stages of the Pneumocystis life cycle. Patients
whosespecimens were negativeforP.jirovecii served as controls.From
May 2000 to May 2008, 173 HIV+ subjects (110 cases, 63 controls)
were enrolled. Among the 63 controls, 45 (71.4%) had community
acquired pneumonia (CAP), 7 (11.1%) had mycobacterial diseases (2
with tuberculosis and 5 with Mycobacterium avium complex (MAC)),
and7(11.1%)hadotherdiseasessuchaspulmonaryKaposisarcoma,
bronchitis, pulmonary fibrosis, and chronic obstructive pulmonary
disease (COPD). Four patients had no discharge diagnosis listed in
chart abstraction. Seven of the patients with CAP had bacteria
cultured in sputum and 2 had MAC isolated in sputum.
Data collection
At hospital admission, clinical and demographic (age, gender,
race) characteristics were collected [32–33]. The clinical data
collected were history of PcP, CD4+ counts, plasma HIV viral
load, serum LDH level, serum albumin levels, arterial blood gas
measurements and the use of mechanical ventilation. The use of
PcP prophylaxis within the last 3 months and PcP treatment
provided were also collected. An acute-phase serum specimen was
drawn at the time of hospital admission and convalescent-phase
serum specimens were drawn every 1–2 weeks for 6 weeks. Serum
specimens were stored at 280uC and shipped to the University of
Cincinnati and the Cincinnati VA Medial Center for analysis.
Recombinant antigens
The recombinant MsgC1 fragment was prepared by PCR using
DNA isolated from P. jirovecii infected lung or cloned Msg genes as
templates and Amplitaq enzyme (Applied Biosystems, Foster City,
CA) to generate msg gene segments [20,24–25]. The PCR products
were cloned into the pET30 vector (Novagen, Madison WI) and
the recombinant MsgC1 proteins were expressed in Escherichia coli
and purified as previously described [24].
IgG ELISA
The ELISA was performed as previously described [25–26,31–
32]. Serum specimens to be analyzed and the standard reference
serum were tested against recombinant MsgC1; PBS without
antigen was used as a negative control. The reactivity of each
serum specimen to Msg was corrected by subtraction of the
reactivity of that serum to PBS (mean OD Msg – mean OD PBS),
and the results were quantified using the method of Bishop and
Kovacs [34]. A standard serum with specificity for MsgC1 was
generated by mixing a pool of 4–6 sera with high reactivity to
MsgC1. A standard curve was generated for MsgC1 on each day
of the assay and was used to calculate the units of reactivity to
MsgC1. The standard serum pool was assigned a value of 100U of
reactivity to MsgC1 construct in 100 mL of a 1: 100 dilution of
serum. Sera were assayed at 1: 100 to 1: 200 dilutions to fit the
linear portion of the standard curves and units of reactivity were
calculated taking the dilution into account.
IgM ELISA
The IgM antibody reactivity to MsgC1 was measured using the
same ELISA methods described above for IgG antibody reactivity
except for the following changes. The secondary antibody was
affinity-purified, HRP-labeled goat anti-human IgM (m chain)
(KPL Products, Gaithersberg, MD) instead of goat anti-human
IgG (H&L) (KPL Products) was used for IgG antibodies. In a
previous study, we tested the anti-IgM reagent for m chain
specificity in two ways: 1) with serum from HIV+ patients with
heavy staining IgM antibody bands to P. jirovecii that had been
separated by column chromatography into IgM and IgG fractions;
and 2) with purified IgM and IgG on immunoblots [11]. In both
cases, anti-IgM antibody only reacted with the IgM preparations,
indicating that it was m chain-specific. As an additional measure of
specificity, we have recently screened 200 healthy blood donors for
IgM and IgG using the same IgG and IgM ELISA. Of 200 serum
samples examined, IgG antibodies were detected in 103 (51.5%) of
the specimens, whereas IgM antibodies were only detected in 7
(3.5%) of the specimens (p,0.001).
Statistical Analysis
Descriptive statistics were calculated to describe patient clinical
and demographic characteristics. Categorical variables were
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associations between MsgC1 antibodies and clinical variables at
initial visit, and the auto-correlation between MsgC1 antibody
responses on the same patient were calculated. The relationship of
PcP infection to MsgC1 antibody levels was determined by the
parameter estimate of dichotomized PcP infection in a linear
mixed model, applied for modeling correlated loge MsgC1
antibody levels with left censoring. Mixed models are often used
for estimating fixed effects and components of variability in
longitudinal studies of continuous data. The model included a
random intercept, which defined MsgC1 antibody values on the
same patient to be correlated. Previous episode of PcP, CD4+
count (,50, $50 cells/mL), and one additional clinical variable,
were modeled as fixed effects, in addition to PcP. Analyses were
repeated when the additional clinical variable was replaced by a
different clinical variable and all other variables remained the
same. MsgC1 antibody responses during the first 6 weeks of
follow-up were analyzed. For each interval, sensitivity and
specificity were calculated for predicting PcP status, when MsgC1
antibody levels were dichotomized as above or below the cut
points. We used parametric receiver operating characteristic
(ROC) curve analysis methods to generate different cutpoints in
each interval. The optimum cutpoint which was the same as the
median value in each time interval was used to calculate the
sensitivity and the specificity. SAS for Windows, version 9.2 (SAS
Institute, Cary, NC) was used for all analyses and the statistical
significance was based on the 5% level. The graphs were produced
using R software, version 2.9 (R project for statistical computing).
Results
Demographic characteristics
At hospital admission, there were statistically significant
differences in gender and racial distributions between PcP cases
and controls (Table S1). The cases were more likely to be males
(88.2% vs. 74.6%) (p=0.02) and Caucasians (52.7% vs. 33.3%)
(p=0.046).
Clinical characteristics
There was no statistical difference in the proportion of patients
with prior episodes of PcP between cases and controls (16% and
23.8% respectively) (Table S1). However, cases had a more
advanced stage of HIV illness with significantly higher median HIV
viral load (1.3610
5 vs. 3.6610
4 copies/mL) (p,0.01) and a higher
proportion of patients with CD4+ counts ,50 cells/ml (62.4% vs.
34.9%) (p,0.01) than controls. Pneumonia severity was similar
between cases and controls. Both groups had similar serum albumin
levels,arterial blood gas measurements, and wereunlikelyto require
mechanical ventilation. However, cases had a significantly higher
median LDH level (347 U/L) compared to controls (283 U/L)
(p,0.01). Fewer cases (20.0%) than controls (39.7%) were taking
PcP prophylaxis within 3 months before hospital admission
(p,0.05). All cases (100%) were treated for PcP while undergoing
diagnostic evaluation compared to 66.7% of the controls (p,0.01),
and the cases were more likely to be treated with trimethoprim-
sulfamethoxazole (TMP-SMX) compared to controls (74.6% vs.
55.6%) (p,0.01). A significant proportion of cases (82.7%) were on
corticosteroids compared to controls (41.3%) (p,0.01).
IgG and IgM antibody levels to MsgC1 at admission and
over time
We compared changes in mean IgG antibody levels to MsgC1 for
a period of up to 6 weeks, and changes in mean IgM antibody levels
to MsgC1 for a period of up to 4 weeks between PcP cases and
controls (Table S1, Figure 1). IgG antibody levels were
s i g n i f i c a n t l yh i g h e ri nt h ec a s e st h a ni nt h ec o n t r o l sa ta l lt i m ep o i n t s
(p,0.05). The IgG antibody levels in the cases increased from 18.15
(95% CI: [14.46–22.78]) at admission to their peak of 29.30 (95% CI:
[17.73–48.42]) at weeks 3–4 and then declined to 18.95 (95% CI:
[10.45–34.37]) at weeks 5–6. However, these changes were not
statistically significant. The IgG antibody levels for the controls
declined from 8.17 (95% CI: [6.55–10.28]) at admission to 2.59 (95%
CI: [1.56–4.27]) at weeks 3–4 and then rose slightly to 5.38 (95% CI:
[2.97–9.77]) at weeks 5–6. The changes in the controls were
statistically significant in the first four weeks of the study (p,0.05).
IgM antibody levels in the cases were significantly higher than
for the controls at the time of hospital admission and at weeks 1–2
thereafter (p,0.05) (Table S1, Figure 1). IgM antibody levels in
the cases were highest at baseline (20.73) and then decreased
slightly over time. Antibody levels in the controls were 9.16 at
baseline, then declined at weeks 1–2 and rose at weeks 3–4.
When serum specimens for the entire 6 weeks period were
combined, PcP cases still had significantly higher mean IgG
antibody levels than controls (mean [95%CI]:17.39 [14.50–20.86]
vs. 7.40 [6.17–8.88]) (p,0.05). Similarly, the combined mean IgM
antibody level to MsgC1 in the cases was higher than that in the
controls (mean [95% CI]: 21.63 [18.69–25.02] vs. 11.51 [9.95–
13.31]) (p,.05). By paired analysis of baseline serum specimens
and 3–4 week specimens, 46% of the cases developed a median
rise of 1.74-fold in IgG antibody levels at weeks 3–4 compared to
14% of the controls with a median rise of 1.03-fold. However, the
difference in proportions was not statistically significant.
We attempted to identify independent risk factors associated
with a rise in IgG antibody levels to MsgC1 among PcP cases at
weeks 3–4. In light of data in our pilot study, we were particularly
interested in the role of first episode of PcP and CD4+ counts. As
seen in Figure 2, there were no significant differences in the
sequential antibody levels to MsgC1 between first episodes and
repeated episodes of PcP. Subjects with CD4+ counts $50 cells/
mL had consistently higher antibody levels during weeks 1–4 than
subjects with CD4+ counts ,50 cells/mL, but these differences
never reached statistical significance.
Use of antibodies to MsgC1 in the diagnosis of PcP
For analysis using IgG and IgM antibody levels to predict PcP
diagnosis, cutpoint values were determined for different time
points. A cutpoint value was defined to be the median value of all
serum specimens from both cases and controls at a given time
point. The IgG cutpoint values increased from baseline to weeks
3–4 and declined afterward (Table 1). A similar pattern was
observed in the sensitivity, specificity, and positive predictive value
(PPV). At hospital admission, an IgG cutpoint of 23 was used to
discriminate cases and controls with 57.2% sensitivity, 61.7%
specificity and 71.5% PPV. By weeks 3–4, an IgG cutpoint of 40.5
was used to discriminate PcP cases and controls with 63.4%
sensitivity, 100% specificity and 100% PPV. Thus, the increase in
PPV over time was mainly due to an increase in specificity, which
reflected changes in antibody levels both in the cases and controls.
In contrast to the IgG cutpoint which increased significantly
over time, the IgM cutpoint decreased slightly over time
(Table 2). Sensitivity, specificity and PPV increased from
59.7%, 61.3%, and 79.3% at admission to 74.6%, 73.7%, and
89.8%, respectively, at weeks 3–4.
Factors associated with high IgG and/or IgM antibody
levels to MsgC1
Here, we were interested in host factors associated with high
antibody levels to MsgC1 rather than a rise or fall in antibody levels
Serologic Diagnosis of PcP
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from both cases and controls as the main dependent variable, we
found that PcP diagnosis and LDH levels were significant predictors
of IgG antibody levels to MsgC1 when controlling for CD4+ count
and previous episode of PcP. PcP diagnosis was significantly
associated with high IgG antibody levels (p,0.01). In contrast,
LDH levels had a negative effect on IgG antibody responses. One
standard deviation increase in loge LDH levels was significantly
associated with decrease in IgG antibody levels (p=0.02). When
IgM was used as the main dependent variable, only PcP diagnosis
was found to be a significant predictor of IgM antibody levels to
MsgC1. PcP diagnosis was significantly associated with increased
IgM antibody levels when controlling for previous episode of PcP
and CD4+ count (p,0.05). LDH was associated with a decrease in
IgM antibody levels, but the effect was not statistically significant.
The effects of CD4+ counts, HIV viral load, PO2 levels and PcP
prophylaxis on both IgM and IgG antibody levels were not
statistically significant. The other variables such as race, gender,
age, PcP treatment, albumin levels and the use of mechanical
ventilation were modeled, but their effects on IgM and IgG
antibody levels were not statistically significant (results not shown).
Discussion
The present study analyzed acute and convalescent serum
antibody responses to MsgC1 in HIV+ subjects with pneumonia
due to P. jirovecii (cases) or other causes (controls) at a single site. The
data showed that the cases had significantly higher IgG and IgM
antibody levels than the controls both at the time of hospital
admission and at intervals for up to one month thereafter. The
sensitivity, specificity and PPV of these specimens increased from
57.2%, 61.7% and 71.5% at admission to 63.4%, 100%, and 100%
at 3–4 weeks, respectively for IgG antibodies, and from 59.7%,
61.3%, and 79.3% at admission to 74.6%, 73.7%, and 89.8%,
respectively for IgM antibodies. Multivariate analysis revealed that
two factors were independently associated with altered antibody
IgG and/or IgM antibody levels: the diagnosis of PcP was
significantly associated with high IgG and IgM antibody levels;
high LDH levels were associated with low IgG antibody levels.
The present report extends the results of our pilot study [32],
but also revealed some differences. For example, the pilot study
found no significant difference in antibody levels to MsgC1
between cases and controls at admission. Yet, that study did find
significant differences in antibody levels between baseline and
weeks 3–4; CD4+ counts ,50 cells/mL and $50 cells/mL; and
first episodes and recurrent episodes of PcP [32]. The present
report found similar trends in these results, but they never reached
statistical significance. Some reasons for these differences may
involve a greater number of subjects in the present report; slight
modifications in the ELISA in the last few years; and differences in
statistical methods used to analyze the data. The analysis in the
pilot study did not take into account values that were below the
Figure 1. Geometric mean [95% CI] IgG and IgM antibody levels to MsgC1 in cases and controls over time. *p,0.05 tests the
differences in mean values between cases and controls at each time point. { tests in controls only the differences in mean values at week 1–2
compared to baseline and at week 3–4 compared to baseline. These comparisons in cases were not significant. A mixed effect Tobit regression model
was written which provided an estimate of the average effect of PcP+ compared to PcP2 in each interval. A random effect subject effect was
modeled to account for correlation between measurements on the same subject in the same interval. The value of the t-statistics, testing Ho: PcP
parameter estimate =0, was used to judge the statistical significance of the effect of PcP+, compared to PcP2.
doi:10.1371/journal.pone.0014259.g001
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model, which was able to handle censored values.
It is difficult to compare our study with previous reports because
most of those studies used different antigen preparations, controls
and methodology [11–19]. In these other studies, HIV+ patients
with PcP exhibited serum antibody levels that were either similar
to or lower than antibody levels of non-PcP patients at the time of
diagnosis [11–15,17]. The PcP patients also had a poor antibody
response in convalescent specimens. Yet, studies of individual
native Pneumocystis antigens suggested how these moieties might be
useful in the future. In one report, technetium-labeled monoclonal
antibodies to Msg showed promise (sensitivity of 85.7%, specificity
of 86.7%) in using lung scans for the diagnosis of PcP [35].
Unfortunately, the test was never commercially developed.
Another report that used native Msg as the antigen found that
HIV+ patients with PcP had more frequent detectable antibodies
and higher antibody levels than HIV+ patients without PcP and
healthy controls [18]. On the other hand, a study that used a
different recombinant Msg fragment than the one used in our
study found high antibody levels in non-HIV immunocompro-
mised patients who experienced PcP; however, there were no
differences in antibody levels in HIV+ patients with PcP, HIV+
patients without PcP, or healthy controls [34].
One way that serology can be used in the diagnosis of infectious
diseases is to demonstrate that the antibody level in a single serum
specimen is above the established normal range of values. The
attractiveness of this approach is that it avoids the need to obtain a
second (convalescent) specimen. The sensitivity, specificity and PPV
Figure 2. Geometric mean [95% CI] IgG antibody levels to MsgC1 in cases by history of PcP and CD4+ cell counts over time.
doi:10.1371/journal.pone.0014259.g002
Table 1. Sensitivity, Specificity, and Positive Predictive Value (PPV) Associated with IgG to MsgC1 Cutpoints at Each Time Interval
Comparing PcP Cases and Controls.
Time Samples in Cases Samples in Controls MsgC1 Cutpoint Sensitivity Specificity PPV
Baseline 180 107 23 57.2 61.7 71.5
1–2 weeks 59 27 25 61.0 70.4 81.8
3–4 weeks 41 11 40.5 63.4 100 100
5–6 weeks 32 16 20.5 53.1 56.3 70.8
Note: We included 110 individual PcP cases and 63 individual controls in this study. Since some patients had their first specimen drawn at the time of hospital
admission, but others had it drawn a day after admission, we defined baseline specimen to be specimen drawn on the day of hospital admission (day 0) or the following
day after admission (day 1). Some subjects had specimens on both days and this resulted into 180 specimens for cases and 107 sample for controls.
doi:10.1371/journal.pone.0014259.t001
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not as good as we had hoped. The reasons for these findings are
unclear but may involve several factors: the severity of HIV and
immunosuppression in the cases; P. jirovecii colonization in the
controls, which can be quite common[10];previous episodesof PcP;
and antibodycross-reactivitywithothermicrobialantigens,although
little is known about this subject. The fact that the cases consistently
had higher antibody levels than the controls and that the specificity
and PPV of the serologic test increased over time is encouraging.
The decrease inantibodylevelscontributed to thesechanges, but the
reasons for this decrease are unknown. It is also possible that the
serologic test will be more sensitive in analyzing differences when
used in non-HIV patients with PcP, as shown in the higher antibody
levels to recombinant Msg in these patients [34].
The other way to use serology as a diagnostic tool is to
demonstrate a rise in antibody levels over time. When serial
dilutions are used to measure antibody levels, a 4-fold or greater
rise is considered to be significant. Yet, in our ELISA, the
determination of what constitutes a significant rise is more
complicated because serum specimens are diluted only once to a
specific level (e.g., 1/100) and the antibody level is then derived
from a standard curve. In addition to the present study, several
other reports have shown that about 40–50% of HIV patients with
PcP develop a rise in antibodies to Msg [18,31–32]. The increase
in antibody levels in these patients helps support the diagnosis of
PcP, but the failure to develop a rise (which occurred in the
majority of cases) does not carry the same negative weight. The
reasons for the relatively low frequency of antibody rises in PcP
subjects are probably related to the advanced stage of HIV disease
and its associated immunosuppression.
In light of the impaired B cell function in HIV infection and the
low or absent IgM antibodies to P. jirovecii antigens in previous
reports [13,16,36–37], the presence of elevated antibody levels in
the present study is somewhat unusual and unexpected. However,
we previously showed that HIV+ patients with single or recurrent
episodes of PcP can develop active IgM and/or IgG responses to
crude P. carinii antigens, and that the secondary anti-IgM
antibody, which was essentially the same product as used here,
was m-specific [11]. In addition, IgM antibodies to specific antigens
have been found in HIV+ patients with CD4+ .100 cells/mL who
were immunized with Haemophilus influenzae Type b vaccine, and in
the saliva of HIV+ patients with Toxoplasma encephalitis [38–39].
The elevated IgM antibodies in the present study might be in
response to new infection, especially if this is the first episode of
PcP. If this is a recurrent episode, there might be a different strain
of P. jirovecii that would elicit this response. One study showed that
some patients who experienced 2 episodes of PcP greater than 6
months apart tended to be infected with different P. jirovecii isolates
rather than the same isolate [40]. Also, the IgM antibodies may
have been elicited by Msg that underwent antigenic variation in an
already acquired strain of P. jirovecii.
The high antibody levels to MsgC1 raise questions about the
host and environmental factors that contribute to them. In a
recent long-term study of HIV+ patients, we found that previous
episode of PcP, geographic location, age and failure to take PcP
prophylaxis were independently associated with increased IgG
antibody levels to the recombinant MsgC1 fragments [31].
However, in the present study, we did not find significant effects
of race, age, and gender on MsgC1 antibody levels. The
discrepancy between this study and our previous report [31]
about the effect of age on MsgC1 antibody levels might be due to
the differences in study design. In that study, MsgC1 antibody
levels were measured on average 6 months after the diagnosis of
PcP, but in this study, it was measured within weeks. As in our
pilot study [32], the cases and controls in the present report
differed significantly in terms of their CD4+ counts, HIV viral
loads, and LDH levels. Other investigators have also found higher
LDH levels in PcP than in other forms of pneumonia [2,4,6–7].
Thus, despite having more advanced HIV disease and more severe
lung damage, cases were still able to develop higher antibody levels
than the controls. Cases in the present report were also
significantly more likely to be male and Caucasian than controls,
whereas in the pilot study these differences did not reach statistical
significance [32]. The influence of race on PcP risk has shown
conflicting results [31,41–42]. Yet, with recent studies showing
that PcP acquisition is influenced by host single nucleotide
polymorphisms (SNPs) in specific genes [43–44], race might have
a role in PcP incidence. Even though more studies are needed to
elucidate this genetic association, the differences in PcP cases
among racial groups found in this study might be due to genetic
variation across different races.
This study has several limitations. It was only performed in
HIV+ patients, who are generally more immunosuppressed than
most other populations at risk for PcP. Thus, the results obtained
here may underestimate the diagnostic value of this serologic test.
Similarly, the population here was entirely composed of adults.
The value of the study in pediatric HIV+ patients with PcP needs
to be evaluated [45]. Since the study was conducted at a single
center, the results may not reasonably apply to hospitals in
different geographic locations. Also, only a minority of control
subjects had an alternative, non-PcP diagnosis confirmed micro-
scopically. While it is possible that these individuals may have had
PcP and a false-negative Diff-Quik test, we have previously shown
a high sensitivity ($98%) and specificity (100%) of this assay at
SFGH [33]. Thus, we believe that we have classified our cases and
controls accurately.
In conclusion, this is the first large scale use of a recombinant P.
jirovecii antigen in the serologic diagnosis of PcP in HIV+ patients.
Table 2. Sensitivity, Specificity, and Positive Predictive Value (PPV) Associated with IgM to MsgC1 Cutpoints at Each Time Interval
Comparing PcP Cases and Controls.
Time Samples in Cases Samples in Control MsgC1 Cutpoint Sensitivity Specificity PPV
Baseline 77 31 23.49 59.7 61.3 79.3
1–2 weeks 77 36 20.39 64.9 69.4 82.0
3–4 weeks 32 19 20.36 74.6 73.7 89.8
Note: We had 110 individual PcP cases and 63 individual controls in this study. Since some patients had their first specimen drawn at the time of hospital admission, but
others had it drawn a day after admission, we defined baseline specimen to be specimen drawn on the day of hospital admission (day 0) or the following day after
admission (day 1). Some subjects had specimens on both days and this resulted into 77 specimens for cases and 31 sample for controls. There are different numbers of
specimens for IgG and IgM in each group because some subjects was not enough for both IgG and IgM antibodies to be tested.
doi:10.1371/journal.pone.0014259.t002
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show promise as an aid to the diagnosis of PcP in situations where
bronchoscopy cannot be performed. This promise may be
increased by evaluating the test in different patient populations
and in different geographic locations; delineating the areas of
maximal reactions on Msg C1 and its closely related other Msg C
fragments; and using Kexin 1 in combination with Msg C1.
Serology may also be useful in conditions such as P. jirovecii
colonization, as evidenced by decreased antibody levels to Kexin 1
[46] and by our finding of low antibody levels to Msg C fragments
in smokers (Walzer, PD unpublished observations). Finally, the
presence of serology as a tool to examine the risk of nosocomial
transmission of P. jirovecii infections may be enhanced by the
findings of increased antibody levels in hospital personnel with
patient contact [27] and the presence of P. jirovecii in the air
surrounding patients with PcP [47].
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